Abstract

Revvity Inc. will report results on August 04, 2026 Pre-Market; this preview compiles last quarter’s performance, consensus forecasts for the current quarter, and the latest institutional commentary on revenue, margins, and adjusted EPS dynamics.

Market Forecast

Consensus for the upcoming quarter points to revenue of 709.03 million US dollars, an EBIT estimate of 191.15 million US dollars, and adjusted EPS of 1.22, implying year-over-year changes of -0.20%, 2.09%, and 7.26% respectively. Management and market expectations imply a broadly stable gross margin profile and a normalized net profit trajectory; adjusted EPS growth is expected to outpace revenue as cost discipline and mix improve. The main businesses are Life Sciences and Diagnostics, with steady demand and a focus on margin-accretive product mix. The most promising segment is Life Sciences, contributing 361.85 million US dollars last quarter; stabilizing biopharma and academic spending suggest improving medium-term growth momentum.

Last Quarter Review

Revvity Inc.’s previous quarter delivered revenue of 711.12 million US dollars, a gross profit margin of 54.51%, GAAP net profit attributable to shareholders of 40.72 million US dollars, a net profit margin of 5.73%, and adjusted EPS of 1.06, with year-over-year growth in adjusted EPS of 4.95% and revenue of 6.97%. Cash discipline and operating efficiency supported profitability as gross margin held above 54%, while adjusted earnings exceeded market expectations. Main business highlights: Life Sciences revenue was 361.85 million US dollars and Diagnostics revenue was 349.27 million US dollars, with Life Sciences showing the largest absolute contribution to quarter revenue.

Current Quarter Outlook (with major analytical insights)

Main business: Balanced Life Sciences and Diagnostics portfolio

Revvity Inc. enters the quarter with a balanced split between Life Sciences and Diagnostics, together driving around 709.03 million US dollars of expected revenue. With the prior quarter’s gross margin at 54.51%, the company’s margin resilience suggests continued pricing and mix discipline in reagents, instrumentation, and consumables. Given a modest top-line decline expectation, attention should be on order conversion, consumable utilization rates, and service attachment to stabilize revenue per customer. A key factor this quarter is the cadence of large-instrument placements in core labs and translational research, which can skew mix and margins. The company’s Diagnostics franchise is poised to benefit from steady volumes in routine testing and a gradual normalization in non-acute panels, helping offset variability in research funding cycles.

Most promising business: Life Sciences mix and efficiency

Life Sciences, contributing 361.85 million US dollars in the last quarter, remains the scale anchor and the most promising profit driver this quarter. The forecasted EPS growth of 7.26% despite a slight revenue dip implies mix improvement and cost alignment within Life Sciences workflows. If consumables attachment rates rise and recent instrument placements accelerate recurring revenue, EBIT leverage of 2.09% year-over-year could be achieved even with flat-to-down volumes. Watch for cross-sell between reagents and informatics offerings to sustain margin accretion. Given macro caution in biopharma and academia, small improvements in purchasing cycles can meaningfully lift utilization and throughput-driven consumables revenue.

Stock-price drivers this quarter: Margins, EPS sensitivity, and guidance

The stock is likely to react to gross margin trends around the prior quarter’s 54.51%, as a 50–100 basis-point swing can drive disproportionate EPS changes given the forecasted revenue profile. Investors will track visibility on order backlog and any updates to cost actions that could underpin the 7.26% EPS growth outlook. Guidance color on fiscal-year revenue and adjusted EPS trajectories will be crucial for sentiment, especially around Diagnostics seasonality and Life Sciences capital spending. Any commentary on pricing sustainability, operational efficiencies, and free-cash-flow conversion will shape the multiple investors are willing to pay in the second half.

Analyst Opinions

Across recent commentary, the prevailing tone is cautiously optimistic, with a majority expecting stable revenue and improving profitability metrics into the quarter. Analysts highlight that the combination of a 2.09% EBIT growth forecast and a 7.26% EPS growth forecast against a slight revenue decline signals ongoing cost control and favorable mix. The bullish camp expects Life Sciences to provide incremental mix benefit and for Diagnostics to deliver steadier volumes, supporting mid-50s gross margins and incremental operating leverage. A minority maintains a more conservative view, citing macro uncertainty in research funding and potential delays in instrument orders, yet they generally acknowledge EPS resilience. Overall, the majority outlook anticipates an in-line revenue print with upside potential on margins and adjusted EPS.